HR 1570 116th Congress House Health Cancer Digestive and metabolic diseases Medical tests and diagnostic methods Medicare

Removing Barriers to Colorectal Cancer Screening Act of 2020

Introduced: March 6, 2019 See on congress.gov

Everywhere this bill has been 13 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Dec 10, 2020

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Dec 9, 2020

The title of the measure was amended. Agreed to without objection.

Dec 9, 2020

Motion to reconsider laid on the table Agreed to without objection.

Dec 9, 2020

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7083-7084)

Dec 9, 2020

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Dec 9, 2020

DEBATE - The House proceeded with forty minutes of debate on H.R. 1570.

Dec 9, 2020

Considered under suspension of the rules. (consideration: CR H7083-7086)

Dec 9, 2020

Mr. Pallone moved to suspend the rules and pass the bill, as amended.

Mar 8, 2019

Sponsor introductory remarks on measure. (CR H2608)

Mar 7, 2019

Referred to the Subcommittee on Health.

Mar 6, 2019

Referred to the Subcommittee on Health.

Mar 6, 2019

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 6, 2019

Introduced in House

Plain-English summary Congressional Research Service

Removing Barriers to Colorectal Cancer Screening Act of 2020

This bill modifies cost-sharing requirements for colorectal cancer screening tests, and drug manufacturer reporting requirements, under Medicare medical services.

Specifically, the bill waives coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure. The bill phases in implementation over an eight-year period.

Additionally, manufacturers of covered drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

What's happening now December 10, 2020

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees of jurisdiction 5